Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-01

Study Completion Date

2026-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) before and after treatment with SGLT2 inhibitors

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure

NCT06137430

SGLT2 Inhibitiors Remodeling Effect Chronic Heart Disease

NOT_YET_RECRUITING

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

NCT05305911

Heart Attack Enlarged Heart

RECRUITING PHASE2

Sodium-glucose Co-transporter 2 Inhibitors Effects in Failing Heart Patients

NCT03977116

Diabetes Mellitus Heart Failure Ventricular Arrythmia

COMPLETED PHASE4

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

NCT05233163

Transthyretin Amyloid Cardiomyopathy

COMPLETED PHASE4

SGLT2i As Anti Arrhythmic Therapy to Prevent Sudden Cardiac Deaths.

NCT03366181

Heart Failure ICD Diabetes Mellitus Type 2 +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetes mellitus (DM) is a chronic metabolic disorder that significantly increases cardiovascular morbidity and mortality. Among the earliest manifestations of diabetic heart disease is subclinical cardiac dysfunction, which includes left atrial (LA) remodeling and impaired LA function.

LA remodeling encompasses changes in atrial size, geometry, wall stress, and mechanical function, and serves as an early marker of diastolic dysfunction and elevated left ventricular (LV) filling pressures.

These changes are key contributors to the development of heart failure, particularly heart failure with preserved ejection fraction (HFpEF)\[4\]and is closely associated with an increased risk of atrial fibrillation (AF).

Conventional echocardiographic parameters often fail to detect early LA dysfunction. Recent advances have highlighted left atrial strain-measured via speckle tracking echocardiography (STE)-as a more sensitive and early marker of LA dysfunction . LA strain assessment, especially during the reservoir, conduit, and contraction phases, provides insights into atrial compliance, stiffness, and overall diastolic function, often preceding structural alterations.

Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors are a class of antihyperglycemic agents that have demonstrated significant cardiovascular benefits in clinical trials. Beyond glycemic control, these agents have been linked to favorable cardiac remodeling, improved diastolic function, and reduced filling pressures. However, their impact on LA function, particularly as assessed by strain parameters, remains underexplored

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SGLT 2 Inhibitors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor

evaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) after treatment with SGLT2 inhibitors

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Empagliflozin Dapagliflozin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed T2DM on antidiabetic medication not including SGLT2 inhibitors.
* HbA1c ≤ 7%.
* Age 40-75 years.
* Sinus rhythm.
* Informed consent obtained

Exclusion Criteria

* History of atrial fibrillation or flutter.
* Patients treated with SGLT2 inhibitors.
* Severe mitral valve regurgitation or stenosis.
* Previous myocardial infarction.
* Previous percutaneous coronary intervention(PCI) or coronary artery bypass grafting (CABG).
* LV Ejection fraction \<50% .
* Severe renal impairment (eGFR \< 30 mL/min/1.73 m²)
* Uncontrolled hypertension (BP \> 160/100 mmHg)
* Inadequate echocardiographic windows or incomplete data

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No